Abstracts Archive - Page 2126 of 2607 - ACR Meeting Abstracts

Abstract Number: 1610 • 2014 ACR/ARHP Annual Meeting
New Autoantigens Associated with Lupus Nephritis
Sachiko Onishi¹, Yuki Tanaka², Tatsuhiko Miyazaki³, Jun Ishizaki¹, Takuya Matsumoto¹, Endy Adnan¹, Hitoshi Yamasaki⁴, Koichiro Suemori¹, Takafumi Okura⁵, Masaki Yasukawa¹ and Hitoshi Hasegawa⁶, ¹Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan, ²Integrated Center for Sciences, Ehime University, Toon, Japan, ³Division of Pathology, Gifu University Hospital, Gifu, Japan, ⁴Department of Hematology, Clinical Immunology, and Infectious Disease, Ehime University Graduate School of Medicine, Toon, Japan, ⁵Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine, Toon, Japan, ⁶Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan
[Background/Purpose ] Systemic lupus erythematosus (SLE) is characterized by the production of a variety of autoantibodies and is considered a prototype immune complex disease. Anti-dsDNA…
Abstract Number: 1609 • 2014 ACR/ARHP Annual Meeting
Dissection of the Type I Interferon Response in Systemic Lupus Erythematosus : Serum IFNα Is Elevated in Lupus Nephritis and Correlates with IFN Score; IFNβ Is Elevated in Mucocutaneous Disease
Julie Ducreux¹, Fabien Colaone², Séverine Nieuwland³, Patrick Blanco⁴, Thierry Defrance⁵, Pierre Vandepapeliere², Géraldine Grouard-Vogel², Frédéric A. Houssiau¹ and Bernard R. Lauwerys¹, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²NEOVACS SA, Paris, France, ³Institut de Recherche Expérimentale et Clinique, Pôle de pathologies rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁴CHU Bordeaux, Bordeaux, France, ⁵INSERM, Lyon, France
Background/Purpose: Type I interferons play a role in the pathogenesis of systemic lupus erythematosus (SLE), but their mechanisms of action are still not fully understood.…
Abstract Number: 1608 • 2014 ACR/ARHP Annual Meeting
Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis
Jill P. Buyon¹, R. Ramsey-Goldman², Richard Furie³, Chaim Putterman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁷Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Biomarkers of renal response in patients with systemic lupus erythematosus (SLE) may provide clues to pathogenesis and drive translation to treatment. This study was…
Abstract Number: 1607 • 2014 ACR/ARHP Annual Meeting
B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare
Mikhail Olferiev¹, Kyriakos A. Kirou² and Mary K. Crow³, ¹Research, HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose Lupus flare reflects an increase of disease activity that is associated with significant morbidity and accumulation of tissue damage. Prediction and prevention of lupus…
Abstract Number: 1606 • 2014 ACR/ARHP Annual Meeting
Profiling a Broad Range of Autoantibodies in Healthy and Systemic Lupus Erythematosis Revealed Autoantibody Patterns Associated with Autoantibody Transition and Disease Activity
Quan-Zhen Li Li¹, Edward Wakeland², Prithvi Raj³, Honglin Zhu², Xiaoxia Zuo⁴, Mei Yan⁵ and Indu Raman⁶, ¹Immunology and internal medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Immunology, University of Texas Southwestern Medical Center, Dallas, TX, ³Immunology, University of Texas Southwestern Medical Center, dallas, TX, ⁴Rheumatology, Xiangya Hospital of Hunan Medical Univ, Changsha, China, ⁵Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁶Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Autoantibodies targeting to nuclear antigens are serological hallmarks of SLE, however, the processing of autoantibody production during the transition from normal to autoimmunity and…
Abstract Number: 1605 • 2014 ACR/ARHP Annual Meeting
Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus
Peter M. Izmirly¹, Robert M. Clancy², Melissa Munroe³, Sara Rasmussen², Amit Saxena^2,4, Jose U. Scher², Aikaterini Thanou⁵, Stan Kamp⁶, Joan T. Merrill⁷, Jill P. Buyon² and Judith James⁸, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mothers of children with neonatal lupus offer a unique opportunity to study the drivers and consequences of autoantibody production in the absence of ongoing…
Abstract Number: 1604 • 2014 ACR/ARHP Annual Meeting
IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria
Rufei Lu^1,2, Melissa E. Munroe³, Joel M. Guthridge², Krista M. Bean², Dustin Fife², John B. Harley⁴, Judith A. James⁵ and Michael P. Keith⁶, ¹Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose Systemic Lupus Erythematosus (SLE) is a clinically diverse autoimmune disease that often begins with a pre-disease period of autoantibody production and symptom accrual.…
Abstract Number: 1603 • 2014 ACR/ARHP Annual Meeting
Effect of Methotrexate on the Immunogenicity of TNF Inhibitors in Spondyloarthritis Patients
Alejandro Villalba¹, Chamaida Plasencia-Rodriguez¹, Diana Peiteado¹, Laura Nuño², Gema Bonilla³, Alejandro Balsa⁴, Emilio Martín-Mola⁵ and Dora Pascual-Salcedo⁶, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Hospital La Paz-IdiPaz, Madrid, Spain, ³Rheumatology, Hospital La Paz, Madrid, Spain, ⁴Reumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁶Immunology, La Paz University Hospital, Madrid, Spain
Background/Purpose: The spondyloarthritis (SpA) patients treated under TNF inhibitors (TNFi) with detectable antidrug antibodies (ADA) often develop loss of efficacy. Concomitant therapy with methotrexate (MTX)…
Abstract Number: 1622 • 2014 ACR/ARHP Annual Meeting
Th1 and Th2 Cytokines Are Associated with Cerebral Atrophy in Systemic Lupus Erythematosus
Mariana Postal¹, Aline T. Lapa¹, Karina de Oliveira Peliçari², Nailu A. Sinicato¹, Fernando Augusto Peres¹, Wesley Geraldo Ferreira², Roberto Marini², Lilian Costallat³, Fernando Cendes⁴ and Simone Appenzeller⁵, ¹Medicine, State University of Campinas, Campinas, Brazil, ²State University of Campinas, Campinas, Brazil, ³Medicine, State University of Campinas, Campinas, United Kingdom, ⁴Neurology, State University of Campinas, Campinas, Brazil, ⁵Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose Cerebral atrophy has been described to occur in systemic lupus erythematosus (SLE) with variable frequency. The pathophysiology of central nervous system (CNS) involvement in…
Abstract Number: 1620 • 2014 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)
Andy Hollins¹, Michael Duryee², Michelene Hearth-Holmes³, Ted R. Mikuls¹, Zhixin Zhang⁴, Kaihong Su⁵ and Geoffrey M. Thiele⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE, ⁶Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose Studies have shown that malondialdehyde-acetaldehyde (MAA) is formed as a result of lipid peroxidation of cellular membranes and is capable of binding or adducting…
Abstract Number: 1621 • 2014 ACR/ARHP Annual Meeting
A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE
Martyna Skwarek, Babett Heschel, Julia Fantana and Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose IL-6 has been found increased in SLE, while CRP, which is directly stimulated by IL-6, usually remains low. We therefore analyzed the IL-6/ IL-6…
Abstract Number: 1619 • 2014 ACR/ARHP Annual Meeting
Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs
David Drubin¹, Xiang Guo², Linglin Yang³, Rong Zeng³, Yuling Wu³, Mustimbo EliPollard Roberts³, Reynald Lescarbeau¹, Aaron Van Hooser¹, Michael Macoritto¹, Michelle Petri⁴ and Wendy White⁵, ¹Selventa, Cambridge, MA, ²Translational Sciences, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Gaithersburg, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose Interferons (IFNs) have long been implicated in the pathogenesis of systemic lupus erythematosus (SLE). However, the specific consequences of the IFN activity have not…
Abstract Number: 1618 • 2014 ACR/ARHP Annual Meeting
Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties
Jing Yao Leong¹, Joo Guan Yeo¹, Thaschawee Arkachaisri² and Jinhua Lu³, ¹Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, ²Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ³Microbiology Department, National University of Singapore, Singapore, Singapore
Background/Purpose Systemic Lupus Erythematosus (SLE) is an autoimmune disease associated with the development of auto-antibodies particularly against nuclear antigens. Previous studies have revealed the possible…
Abstract Number: 1617 • 2014 ACR/ARHP Annual Meeting
Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes
Zhongbo Jin¹, Mark A. Jensen², Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin³, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁶, Kevin G. Moder⁴, Vaidehi Chowdhary³ and Timothy B. Niewold¹, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Dept of Rheumatology, Mayo Clinc, Rochester, MN
Background/Purpose Type I interferon (IFN) is a primary pathogenic factor in human systemic lupus erythematosus (SLE). IFN gene expression signatures have been observed in whole blood and mixed peripheral…
Abstract Number: 1598 • 2014 ACR/ARHP Annual Meeting
Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis
Hanna Przepiera-Bedzak¹, Katarzyna Fischer² and Marek Brzosko¹, ¹Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland, ²Independent Laboratory of Rheumatic Diagnostics, Pomeranian Medical University in Szczecin, Szczecin, Poland
Background/Purpose In recent years, increased incidences of metabolic disorders have been observed in patients with systemic inflammatory rheumatic diseases. Fetuin-A, Intercellular Adhesion Molecule -1(ICAM-1) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].